

David N Franz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/497194/publications.pdf>

Version: 2024-02-01

82
papers

10,070
citations

87888

38
h-index

64796

79
g-index

83
all docs

83
docs citations

83
times ranked

6939
citing authors

#	ARTICLE	IF	CITATIONS
1	Tuberous Sclerosis Complex Diagnostic Criteria Update: Recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. <i>Pediatric Neurology</i> , 2013, 49, 243-254.	2.1	1,185
2	Sirolimus for Angiomyolipoma in Tuberous Sclerosis Complex or Lymphangiomyomatosis. <i>New England Journal of Medicine</i> , 2008, 358, 140-151.	27.0	1,138
3	Everolimus for Subependymal Giant-Cell Astrocytomas in Tuberous Sclerosis. <i>New England Journal of Medicine</i> , 2010, 363, 1801-1811.	27.0	906
4	Tuberous Sclerosis Complex Surveillance and Management: Recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. <i>Pediatric Neurology</i> , 2013, 49, 255-265.	2.1	693
5	Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. <i>Lancet</i> , The, 2013, 381, 125-132.	13.7	687
6	Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. <i>Annals of Neurology</i> , 2006, 59, 490-498.	5.3	572
7	Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study. <i>Lancet</i> , The, 2016, 388, 2153-2163.	13.7	554
8	Everolimus treatment of refractory epilepsy in tuberous sclerosis complex. <i>Annals of Neurology</i> , 2013, 74, 679-687.	5.3	332
9	Mutational and Radiographic Analysis of Pulmonary Disease Consistent with Lymphangiomyomatosis and Micronodular Pneumocyte Hyperplasia in Women with Tuberous Sclerosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2001, 164, 661-668.	5.6	266
10	Updated International Tuberous Sclerosis Complex Diagnostic Criteria and Surveillance and Management Recommendations. <i>Pediatric Neurology</i> , 2021, 123, 50-66.	2.1	230
11	Mosaic and Intronic Mutations in TSC1/TSC2 Explain the Majority of TSC Patients with No Mutation Identified by Conventional Testing. <i>PLoS Genetics</i> , 2015, 11, e1005637.	3.5	209
12	<i>GRIN2B</i> encephalopathy: novel findings on phenotype, variant clustering, functional consequences and treatment aspects. <i>Journal of Medical Genetics</i> , 2017, 54, 460-470.	3.2	190
13	Everolimus long-term safety and efficacy in subependymal giant cell astrocytoma. <i>Neurology</i> , 2013, 80, 574-580.	1.1	180
14	Multicenter Phase 2 Trial of Sirolimus for Tuberous Sclerosis: Kidney Angiomyolipomas and Other Tumors Regress and VEGF- D Levels Decrease. <i>PLoS ONE</i> , 2011, 6, e23379.	2.5	177
15	Subependymal Giant Cell Astrocytoma: Diagnosis, Screening, and Treatment. Recommendations From the International Tuberous Sclerosis Complex Consensus Conference 2012. <i>Pediatric Neurology</i> , 2013, 49, 439-444.	2.1	157
16	Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 study. <i>Lancet Oncology</i> , The, 2014, 15, 1513-1520.	10.7	152
17	Long-Term Use of Everolimus in Patients with Tuberous Sclerosis Complex: Final Results from the EXIST-1 Study. <i>PLoS ONE</i> , 2016, 11, e0158476.	2.5	146
18	Everolimus for subependymal giant cell astrocytoma: 5-year final analysis. <i>Annals of Neurology</i> , 2015, 78, 929-938.	5.3	130

#	ARTICLE	IF	CITATIONS
19	Long-term treatment of epilepsy with everolimus in tuberous sclerosis. <i>Neurology</i> , 2016, 87, 2408-2415.	1.1	130
20	Lymphangiomyomatosis Screening in Women With Tuberous Sclerosis. <i>Chest</i> , 2013, 144, 578-585.	0.8	129
21	Identification of S664 TSC2 Phosphorylation as a Marker for Extracellular Signal-Regulated Kinase-Mediated mTOR Activation in Tuberous Sclerosis and Human Cancer. <i>Cancer Research</i> , 2007, 67, 7106-7112.	0.9	128
22	Regression of a Cardiac Rhabdomyoma in a Patient Receiving Everolimus. <i>Pediatrics</i> , 2011, 127, e1335-e1337.	2.1	100
23	Everolimus for treatment-refractory seizures in TSC. <i>Neurology: Clinical Practice</i> , 2018, 8, 412-420.	1.6	85
24	Autism and the cerebellum: evidence from tuberous sclerosis. <i>Journal of Autism and Developmental Disorders</i> , 2000, 30, 511-517.	2.7	84
25	The effect of everolimus on renal angiomyolipoma in patients with tuberous sclerosis complex being treated for subependymal giant cell astrocytoma: subgroup results from the randomized, placebo-controlled, Phase 3 trial EXIST-1. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 1203-1210.	0.7	79
26	Adjunctive everolimus for children and adolescents with treatment-refractory seizures associated with tuberous sclerosis complex: post-hoc analysis of the phase 3 EXIST-3 trial. <i>The Lancet Child and Adolescent Health</i> , 2018, 2, 495-504.	5.6	77
27	Everolimus in tuberous sclerosis patients with intractable epilepsy: A treatment option?. <i>European Journal of Paediatric Neurology</i> , 2013, 17, 631-638.	1.6	73
28	A systematic review on the burden of illness in individuals with tuberous sclerosis complex (TSC). <i>Orphanet Journal of Rare Diseases</i> , 2020, 15, 23.	2.7	69
29	Everolimus: an mTOR inhibitor for the treatment of tuberous sclerosis. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 1181-1192.	2.4	68
30	Everolimus alters white matter diffusion in tuberous sclerosis complex. <i>Neurology</i> , 2012, 78, 526-531.	1.1	67
31	Everolimus in the treatment of subependymal giant cell astrocytomas, angiomyolipomas, and pulmonary and skin lesions associated with tuberous sclerosis complex. <i>Biologics: Targets and Therapy</i> , 2013, 7, 211.	3.2	55
32	Non-Neurologic Manifestations of Tuberous Sclerosis Complex. <i>Journal of Child Neurology</i> , 2004, 19, 690-698.	1.4	54
33	Short-term safety of mTOR inhibitors in infants and very young children with tuberous sclerosis complex (TSC): Multicentre clinical experience. <i>European Journal of Paediatric Neurology</i> , 2018, 22, 1066-1073.	1.6	54
34	Current Management of Tuberous Sclerosis Complex. <i>Paediatric Drugs</i> , 2008, 10, 299-313.	3.1	49
35	Molecular Therapies for Tuberous Sclerosis and Neurofibromatosis. <i>Current Neurology and Neuroscience Reports</i> , 2012, 12, 294-301.	4.2	48
36	mTOR inhibitor therapy as a disease modifying therapy for tuberous sclerosis complex. <i>American Journal of Medical Genetics, Part C: Seminars in Medical Genetics</i> , 2018, 178, 365-373.	1.6	44

#	ARTICLE	IF	CITATIONS
37	Lamotrigine Therapy of Epilepsy in Tuberous Sclerosis. <i>Epilepsia</i> , 2001, 42, 935-940.	5.1	41
38	Everolimus dosing recommendations for <scp>tuberous sclerosis complexâ€™</scp>associated refractory seizures. <i>Epilepsia</i> , 2018, 59, 1188-1197.	5.1	41
39	mTOR inhibitors in the pharmacologic management of tuberous sclerosis complex and their potential role in other rare neurodevelopmental disorders. <i>Orphanet Journal of Rare Diseases</i> , 2017, 12, 51.	2.7	38
40	Cannabidiol Elevates Mechanistic Target of Rapamycin Inhibitor Levels in Patients With Tuberous Sclerosis Complex. <i>Pediatric Neurology</i> , 2020, 105, 59-61.	2.1	38
41	Levetiracetam as Adjunctive Antiepileptic Therapy for Patients with Tuberous Sclerosis Complex: A Retrospective Open-Label Trial. <i>Journal of Child Neurology</i> , 2006, 21, 53-57.	1.4	37
42	The effect of everolimus on renal angiomyolipoma in pediatric patients with tuberous sclerosis being treated for subependymal giant cell astrocytoma. <i>Pediatric Nephrology</i> , 2018, 33, 101-109.	1.7	37
43	Utility of [18 F]2-Fluoro-2-Deoxyglucose-PET in Sporadic and Tuberous Sclerosis-Associated Lymphangiomyomatosis. <i>Chest</i> , 2009, 136, 926-933.	0.8	33
44	Everolimus as adjunctive therapy for tuberous sclerosis complex-associated partial-onset seizures. <i>Expert Review of Neurotherapeutics</i> , 2019, 19, 913-925.	2.8	33
45	Effect of everolimus on renal function in patients with tuberous sclerosis complex: evidence from EXIST-1 and EXIST-2. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 1000-1008.	0.7	31
46	Response to everolimus is seen in TSC-associated SEGAs and angiomyolipomas independent of mutation type and site in TSC1 and TSC2. <i>European Journal of Human Genetics</i> , 2015, 23, 1665-1672.	2.8	29
47	Safety of Everolimus in Patients Younger than 3 Years of Age: Results from EXIST-1, a Randomized, Controlled Clinical Trial. <i>Journal of Pediatrics</i> , 2016, 172, 151-155.e1.	1.8	29
48	Research and innovation in the development of everolimus for oncology. <i>Expert Opinion on Drug Discovery</i> , 2011, 6, 323-338.	5.0	24
49	Everolimus for Tumor Recurrence After Surgical Resection for Subependymal Giant Cell Astrocytoma Associated With Tuberous Sclerosis Complex. <i>Journal of Child Neurology</i> , 2013, 28, 602-607.	1.4	22
50	Improvement in Renal Cystic Disease of Tuberous Sclerosis Complex After Treatment with Mammalian Target of Rapamycin Inhibitor. <i>Journal of Pediatrics</i> , 2017, 187, 318-322.e2.	1.8	22
51	Measuring Health-Related Quality of Life in Tuberous Sclerosis Complex â€™ Psychometric Evaluation of Three Instruments in Individuals With Refractory Epilepsy. <i>Frontiers in Pharmacology</i> , 2018, 9, 964.	3.5	22
52	Clinical Letter: A case report of targeted therapy with sirolimus for NPRL3 epilepsy. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2019, 73, 43-45.	2.0	22
53	Longitudinal Effects of Everolimus on White Matter Diffusion in Tuberous Sclerosis Complex. <i>Pediatric Neurology</i> , 2019, 90, 24-30.	2.1	21
54	Calcification in cerebral parenchyma affects pharmacoresistant epilepsy in tuberous sclerosis. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2018, 60, 86-90.	2.0	20

#	ARTICLE	IF	CITATIONS
55	Pharmacological treatment strategies for subependymal giant cell astrocytoma (SEGA). <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 1329-1336.	1.8	20
56	Vigabatrin for Childhood Partial-Onset Epilepsies. <i>Pediatric Neurology</i> , 2012, 46, 83-88.	2.1	19
57	Profile of everolimus in the treatment of tuberous sclerosis complex: an evidence-based review of its place in therapy. <i>Neuropsychiatric Disease and Treatment</i> , 2016, Volume 12, 2165-2172.	2.2	17
58	Acute Management of Symptomatic Subependymal Giant Cell Astrocytoma With Everolimus. <i>Pediatric Neurology</i> , 2017, 72, 81-85.	2.1	17
59	RHOA signaling defects result in impaired axon guidance in iPSC-derived neurons from patients with tuberous sclerosis complex. <i>Nature Communications</i> , 2021, 12, 2589.	12.8	17
60	Prenatal Sirolimus Treatment for Rhabdomyomas in Tuberous Sclerosis. <i>Pediatric Neurology</i> , 2021, 125, 26-31.	2.1	16
61	Adjunctive everolimus therapy for tuberous sclerosis complex-associated refractory seizures: Results from the postextension phase of EXIST-3. <i>Epilepsia</i> , 2021, 62, 3029-3041.	5.1	16
62	Tuberin Regulates Prostaglandin Receptor-Mediated Viability, via Rheb, in mTORC1-Hyperactive Cells. <i>Molecular Cancer Research</i> , 2017, 15, 1318-1330.	3.4	14
63	Nursing Implications for the Lifelong Management of Tuberous Sclerosis Complex. <i>Journal of Neuroscience Nursing</i> , 2013, 45, 226-242.	1.1	13
64	Congenital Lymphatic Malformation and Aortic Aneurysm in a Patient with TSC2 Mutation. <i>Neuropediatrics</i> , 2020, 51, 057-061.	0.6	12
65	Pharmacotherapeutic Management of Pediatric Gliomas. <i>Paediatric Drugs</i> , 2013, 15, 29-42.	3.1	10
66	Lymphangioliomyomatosis Association with Underlying Genotype in Patients with Tuberous Sclerosis Complex. <i>Annals of the American Thoracic Society</i> , 2021, 18, 815-819.	3.2	10
67	Pooled analysis of menstrual irregularities from three major clinical studies evaluating everolimus for the treatment of tuberous sclerosis complex. <i>PLoS ONE</i> , 2017, 12, e0186235.	2.5	10
68	Thoracoabdominal imaging of tuberous sclerosis. <i>Pediatric Radiology</i> , 2018, 48, 1307-1323.	2.0	7
69	Frequency, Progression, and Current Management: Report of 16 New Cases of Nonfunctional Pancreatic Neuroendocrine Tumors in Tuberous Sclerosis Complex and Comparison With Previous Reports. <i>Frontiers in Neurology</i> , 2021, 12, 627672.	2.4	7
70	Everolimus for cognition/autism in children with tuberous sclerosis complex. <i>Neurology</i> , 2019, 93, 51-52.	1.1	5
71	Symptom rates and profile clustering in tuberous sclerosis complex-associated neuropsychiatric disorders (TAND). <i>Journal of Neurodevelopmental Disorders</i> , 2021, 13, 60.	3.1	5
72	Targeting mTOR complex 1 to treat neurological and psychiatric manifestations of tuberous sclerosis complex. <i>Future Neurology</i> , 2011, 6, 261-271.	0.5	3

#	ARTICLE	IF	CITATIONS
73	Diabetes in Individuals With Tuberous Sclerosis Complex Treated With mTOR Inhibitors. <i>Pediatric Neurology</i> , 2021, 120, 7-10.	2.1	3
74	Effect of everolimus on angiogenic biomarkers in patients with tuberous sclerosis complex (TSC): Results from EXIST-1 and EXIST-2.. <i>Journal of Clinical Oncology</i> , 2012, 30, 10619-10619.	1.6	2
75	Prevalence of thoracoabdominal imaging findings in tuberous sclerosis complex. <i>Orphanet Journal of Rare Diseases</i> , 2022, 17, 124.	2.7	2
76	Renal Lesions in Lymphangioliomyomatosis and Tuberous Sclerosis Complex Are Rarely Biologically Aggressive. <i>American Journal of Roentgenology</i> , 2018, 210, W131-W131.	2.2	1
77	mTOR Inhibitor Therapy for Tuberous Sclerosis Complex: Longitudinal Study of Muscle Mass Determined by Abdominal Cross-sectional Imaging with CT and MRI. <i>Radiology Imaging Cancer</i> , 2020, 2, e190091.	1.6	1
78	Stomatitis incidence and its relationship with efficacy: A meta-analysis of everolimus clinical studies.. <i>Journal of Clinical Oncology</i> , 2014, 32, 151-151.	1.6	1
79	Meta-analysis of stomatitis incidence in everolimus (EVE) clinical studies and its relationship with efficacy.. <i>Journal of Clinical Oncology</i> , 2014, 32, 645-645.	1.6	1
80	Reply. <i>Annals of Neurology</i> , 2014, 75, 164-165.	5.3	0
81	Pharmacologic management of tuberous sclerosis complex-associated subependymal giant cell astrocytomas. <i>Expert Opinion on Orphan Drugs</i> , 2014, 2, 53-66.	0.8	0
82	Anticonvulsant Agents: Everolimus. , 2020, , 1-32.		0